enVVeno Medical Corporation (NASDAQ:NVNO) announced a 1‑for‑35 reverse stock split of its common stock, a move designed to lift the share price above Nasdaq’s $1.00 minimum bid‑price requirement and preserve the company’s listing. The split will become effective at 12:01 a.m. Eastern time on January 20, 2026, consolidating roughly 22.9 million shares into about 655,000 shares and raising the per‑share price to roughly $1.50.
The reverse split follows a notice from Nasdaq on October 7, 2025, that the company’s stock had traded below $1.00 for 30 consecutive business days. enVVeno must regain compliance by April 6, 2026, or face delisting. The board’s decision is part of a broader plan to stabilize the company’s financial position, which has been under pressure from significant operating losses and regulatory setbacks.
Financially, enVVeno reported a trailing‑12‑month loss of $22.0 million and a Q3 2025 net loss of $4.5 million, with a cash burn of $4.2 million in that quarter. As of September 30, 2025, the company held $31.0 million in cash and investments, projected to fund operations through Q2 2027, excluding the costs associated with commercializing its VenoValve device and the enVVe IDE study.
The company’s lead product, the VenoValve, faced a regulatory hurdle when the FDA appealed an unfavorable decision in November 2025. The reverse split is therefore a short‑term measure to address liquidity and compliance while the company continues to pursue its product pipeline.
CEO Robert Berman said the reverse split is “an important first step in a multi‑part plan for 2026 that we expect will create value for shareholders and reestablish our roadmap for enVVeno Medical to become the preeminent company for treating deep venous disease.” He added that the company will reveal further strategic initiatives in the coming weeks.
Market reaction to the announcement was negative, with the stock falling 19.69 % in pre‑market trading to $0.2761. Investors view the reverse split as a signal of ongoing financial distress, compounded by the company’s prolonged decline in share price and the unfavorable FDA decision.
The reverse split is a material event that could influence long‑term investment decisions, as it reflects the company’s need to address compliance and liquidity challenges while it works to bring its products to market.
revised_sentiment_rating
importance
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.